OPKO Health (OPK)
(Delayed Data from NSDQ)
$1.51 USD
0.00 (0.00%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $1.52 +0.01 (0.66%) 7:58 PM ET
2-Buy of 5 2
C Value D Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.51 USD
0.00 (0.00%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $1.52 +0.01 (0.66%) 7:58 PM ET
2-Buy of 5 2
C Value D Growth D Momentum F VGM
Zacks News
Here's Why You Should Hold Onto Opko Health (OPK) Stock Now
by Zacks Equity Research
Opko Health's (OPK) strong focus in R&D bodes well. However, the company faces cutthroat competition in the niche space.
Options Traders Expect Huge Moves in OPKO Health (OPK) Stock
by Zacks Equity Research
Investors in OPKO Health (OPK) need to pay close attention to the stock based on moves in the options market lately.
Opko Health (OPK) Rallies on Q1 Earnings and Revenue Beat
by Zacks Equity Research
Opko Health (OPK) gains from solid pharmaceutical business in the first quarter of 2018.
Implied Volatility Surging for Opko Health (OPK) Stock Options
by Zacks Equity Research
Surging implied volatility makes Opko Health (OPK) lucrative to the option traders.
OPKO Health (OPK) Q4 Earnings Decline Y/Y, Margins Down
by Zacks Equity Research
OPKO Health (OPK) posts lackluster Q4 numbers due to rising operating expenses owing to investments associated with the launch of RAYALDEE and consistent investments in the pharmaceutical pipeline.
Why OPKO Health (OPK) Could Be Positioned for a Slump
by Zacks Equity Research
OPKO Health (OPK) has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions as well.
4 Medical Device Stocks to Top Q3 Earnings
by Zacks Equity Research
A look at how medical device players are poised for this earnings season.
OPKO Health (OPK) Signs New Agreement with Japan Tobacco
by Zacks Equity Research
OPKO Health's (OPK) new agreement with Japan Tobacco will enhance prospects of its kidney drug RAYALDEE in Japan.
Is the Options Market Predicting a Spike in Opko Health (OPK) Stock?
by Zacks Equity Research
Investors in Opko Health (OPK) need to pay close attention to the stock based on moves in the options market lately.
OPKO Health (OPK) Posts Narrower-than-Estimated Loss in Q2
by Zacks Equity Research
OPKO Health (OPK) posted lackluster Q2 numbers due to rising operating expenses owing to investment associated to the launch of RAYALDEE, and consistent investment in the pharmaceutical pipeline.
Med-Product Stocks Aug 8 Earnings Roster: HSIC, AGIO & More
by Zacks Equity Research
Long-term tailwinds including M&A, emerging markets, positive demographic trends and new product innovation might bode well for the medical device industry.
Is the Options Market Predicting a Spike in Opko Health (OPK) Stock?
by Zacks Equity Research
Surging level of implied volatility makes Opko Health (OPK) Stock lucrative to the option traders.
Medical Product Q1 Earnings on May 8: ITGR, OPK & More
by Zacks Equity Research
Let's take a look at the major Medical products stocks slated to release their first-quarter 2017 reports on May 8.
OPKO Health (OPK) Launches Prenatal Testing Tool ClariTest
by Zacks Equity Research
OPKO Health Inc. (OPK) recently announced the launch of a non-invasive medical test to detect fetal abnormalities.
Biotech Stock Roundup: Inotek Plunges on Pipeline Setback, Kite Files IND for Study Initiation
by Arpita Dutt
Although this was a relatively slow week for the biotech sector, Inotek (ITEK) made it to the headlines on disappointing data on its lead pipeline drug.
OPKO Health (OPK) Reports Failure in hGH-CTP Phase 3
by Zacks Equity Research
OPKO Health Inc. (OPK) announced failure in its data analysis of the Phase 3 Clinical Study of hGH-CTP in Growth Hormone Deficient Adults.
4 Medical Device Stocks on a Bull Run this Earnings Season
by Zacks Equity Research
The expected positive third-quarter performance by the broader Medical sector is something investors definitely need to muse on.